TCH-013

antineoplastic; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Henry, R William: 3 articles (03/2013 - 07/2012)
2.	Hovde, Stacy: 3 articles (03/2013 - 07/2012)
3.	Lansdell, Theresa A: 3 articles (03/2013 - 07/2012)
4.	Tepe, Jetze J: 3 articles (03/2013 - 07/2012)
5.	Azevedo, Lauren M: 2 articles (11/2012 - 07/2012)
6.	Cornicelli, Joseph A: 2 articles (11/2012 - 07/2012)
7.	Kahlon, Daljinder K: 2 articles (11/2012 - 07/2012)
8.	McCormick, J Justin: 2 articles (11/2012 - 07/2012)
9.	O'Reilly, Sandra: 2 articles (11/2012 - 07/2012)
10.	Woolliscroft, Tracey: 2 articles (11/2012 - 07/2012)

1.	Arthritis (Polyarthritis) 11/15/2012 - "We report herein that the orally available imidazoline-based NF-κB inhibitor, TCH-013, was found to significantly reduce TNF-α signaling and attenuate collagen antibody induced arthritis in BALB/c mice." 07/15/2012 - "We report herein that the orally available imidazoline-based NF-κB inhibitor, TCH-013, was found to significantly reduce TNF-α signaling and attenuate collagen antibody induced arthritis in BALB/c mice."
2.	Neoplasms (Cancer) 03/15/2013 - "The cellular activity translated well in vivo where TCH-013 delayed tumor growth in an MM xenograft model to a similar extent as bortezomib."
3.	Leukemia 03/15/2013 - "Importantly, TCH-013 induces apoptosis in a panel of myeloma and leukemia cell lines, but in contrast, normal lymphocytes, primary bone marrow stromal cells (hBMSC), and macrophages are resistant to its cytotoxic effects. "